Advanced search
Publication Cover
Future Oncology Volume 18, 2022 - Issue 31
Submit an article Journal homepage
2,495
Views
0
CrossRef citations to date
0
Altmetric
Clinical Trial Protocol

KEYNOTE – D36: Personalized Immunotherapy with a Neoepitope Vaccine, EVX-01 and Pembrolizumab in Advanced Melanoma

Georgina V Long1 Melanoma Institute Australia, The University of Sydney, & Royal North Shore & Mater Hospitals, Sydney, New South Wales, 2065, AustraliaORCID Iconhttps://orcid.org/0000-0001-8894-3545
ORCID Icon,
Pier Francesco Ferrucci2 Cancer Biotherapy Unit, Department of Experimental Oncology, European Institute of Oncology IRCCS, Milan, 20139, ItalyORCID Iconhttps://orcid.org/0000-0001-6255-5851
ORCID Icon,
Adnan Khattak3 Hollywood Private Hospital & Edith Cowan University, Perth, 6009, AustraliaORCID Iconhttps://orcid.org/0000-0002-4633-3818
ORCID Icon,
Tarek M Meniawy4 Linear Cancer Trials, Nedlands, 6009, Australia
,
Patrick Alexander Ott5 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA02215, USA
,
Michael Chisamore6 Merck & Co., Inc., 126 E. Lincoln Avenue, Rahway, NJ07065, USA
,
Thomas Trolle7 Evaxion Biotech A/S, Dr. Neergaards Vej 5F, Hørsholm, 2970, DenmarkORCID Iconhttps://orcid.org/0000-0003-0762-2198
ORCID Icon,
Agon Hyseni7 Evaxion Biotech A/S, Dr. Neergaards Vej 5F, Hørsholm, 2970, Denmark
&
Erik Heegaard7 Evaxion Biotech A/S, Dr. Neergaards Vej 5F, Hørsholm, 2970, DenmarkCorrespondence[email protected]
 show all
Pages 3473-3480 | Received 11 Jul 2022, Accepted 11 Aug 2022, Published online: 01 Sep 2022

References

  • Hamid O , RobertC, DaudAet al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann. Oncol.30(4), 582–588 (2019).
  • Larkin J , Chiarion-SileniV, GonzalezRet al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med.381(16), 1535–1546 (2019).
  • Robert C , SchachterJ, LongGvet al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med.372(26), 2521–2532 (2015).
  • Hamid O , RobertC, DaudAet al. Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006. Eur. J. Cancer157, 391–402 (2021).
  • Gubin MM , ZhangX, SchusterHet al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature515(7528), 577–581 (2014).
  • van Rooij N , van BuurenMM, PhilipsDet al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J. Clin. Oncol.31(32), 439–442 (2013).
  • Lu Y-C , YaoX, LiYFet al. Mutated PPP1R3B is recognized by T cells used to treat a melanoma patient who experienced a durable complete tumor regression. J. Immunol.190(12), 6034–6042 (2013).
  • Zhou J , DudleyME, RosenbergSA, RobbinsPF. Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy. Journal of Immunotherapy28(1), 53–62 (2005).
  • Keskin DB , AnandappaAJ, SunJet al. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature565(7738), 234–239 (2019).
  • Ott PA , HuZ, KeskinDBet al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature547(7662), 217–221 (2017).
  • Ralli M , BotticelliA, ViscontiICet al. Immunotherapy in the treatment of metastatic melanoma: current knowledge and future directions. J. Immunol. Res.2020, 9235638 (2020).
  • Sahin U , DerhovanessianE, MillerMet al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature547(7662), 222–226 (2017).
  • Ott PA , Hu-LieskovanS, ChmielowskiBet al. A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. Cell183(2), 347–362 (2020).
  • Mørk SK , KadivarM, BolKFet al. Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF®09b, in patients with metastatic melanoma. OncoImmunology11(1), 2023255 (2022).
  • Guo Y , LeiK, TangL. Neoantigen vaccine delivery for personalized anticancer immunotherapy. Front. Immunol.9, 1499 (2018).
  • Eisenhauer EA , TherasseP, BogaertsJet al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer45(2), 228–247 (2009).
  • Amin MB , EdgeSB, GreeneFLet al. American Joint Committee on Cancer (AJCC). Cancer J. Clin.67(2), 93–99 (2017).
  • Seymour L , BogaertsJ, PerroneAet al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol.18(3), e143–e152 (2017).

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.